GO:0102390 mycophenolic acid acyl-glucuronide esterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0102390 describes the enzymatic hydrolysis of mycophenolic acid O-acyl-glucuronide to release mycophenolate, a potent immunosuppressant.
• The reaction is catalyzed by ABHD10, a serine hydrolase that acts as an acyl-glucuronide esterase in human liver.
• This activity is critical for the pharmacokinetics of mycophenolate mofetil, a prodrug used in solid organ transplantation.
• ABHD10 belongs to the alpha/beta hydrolase fold family, which includes many orphan esterases involved in drug metabolism and detoxification.
• Deficiency or inhibition of this activity can lead to accumulation of acyl-glucuronide metabolites, potentially causing toxicity.
• Studying GO:0102390 helps researchers understand interindividual variability in mycophenolate exposure and adverse effects.
Description
Mycophenolic acid acyl-glucuronide esterase activity (GO:0102390) is a molecular function that catalyzes the hydrolysis of mycophenolic acid O-acyl-glucuronide(1-) to yield mycophenolate, a proton, and D-glucopyranuronate. This reaction is part of the metabolic pathway of mycophenolic acid, an immunosuppressive drug widely used to prevent organ transplant rejection. The enzyme responsible for this activity in human liver is alpha/beta hydrolase domain-containing protein 10 (ABHD10), which was identified as the major acyl-glucuronide esterase for mycophenolic acid. Understanding this activity is essential for predicting drug clearance, efficacy, and toxicity in transplant patients. The importance of GO:0102390 extends beyond transplantation. Acyl-glucuronide metabolites of various drugs can be reactive and cause idiosyncratic adverse reactions, and esterases like ABHD10 may play a protective role by hydrolyzing these metabolites. Therefore, this GO term represents a key node in drug metabolism and detoxification pathways. Researchers studying drug-induced toxicity, pharmacokinetics, and personalized medicine need to consider the role of this enzymatic activity. In this article, we provide a comprehensive overview of GO:0102390, including its definition, mechanism, key genes, disease associations, and research methods. We also highlight how CRISPR-based models can be used to investigate this activity and its physiological relevance.
mycophenolic acid acyl-glucuronide esterase activity At A Glance
| GO ID | GO:0102390 |
|---|---|
| GO term | mycophenolic acid acyl-glucuronide esterase activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Catalysis of the reaction: mycophenolic acid O-acyl-glucuronide(1-) + H2O = mycophenolate + H+ + D-glucopyranuronate. |
| Major function | Hydrolysis of mycophenolic acid acyl-glucuronide to release active mycophenolate |
| Enzyme class | Esterase (serine hydrolase) |
| Key enzyme | ABHD10 (alpha/beta hydrolase domain-containing protein 10) |
| Subcellular location | Cytosol (inferred from ABHD10 localization) |
What Is GO:0102390?
According to the Gene Ontology, GO:0102390 is defined as the catalysis of the reaction: mycophenolic acid O-acyl-glucuronide(1-) + H2O = mycophenolate + H+ + D-glucopyranuronate. In simpler terms, it is an enzymatic activity that removes a glucuronide group from mycophenolic acid acyl-glucuronide, regenerating the active drug mycophenolate. This activity is a type of esterase activity, specifically acting on acyl-glucuronide esters.
Why Is mycophenolic acid acyl-glucuronide esterase activity Important in Cell Biology?
GO:0102390 is important because it directly influences the pharmacokinetics and pharmacodynamics of mycophenolate, a cornerstone immunosuppressant used in solid organ transplantation. By regenerating active mycophenolate from its acyl-glucuronide metabolite, this activity can modulate drug exposure and potentially reduce toxicity associated with acyl-glucuronide accumulation. Moreover, understanding this activity sheds light on the broader roles of orphan esterases in drug metabolism and detoxification, which are increasingly recognized as determinants of interindividual variability in drug response.
• Regulates the levels of active mycophenolate, affecting immunosuppressive efficacy.
• Prevents accumulation of mycophenolic acid acyl-glucuronide, which may cause gastrointestinal toxicity.
• Represents a key pathway for the metabolism of acyl-glucuronide metabolites of various drugs.
• ABHD10, the enzyme responsible, is a member of the serine hydrolase superfamily with broad substrate specificity.
• Interindividual differences in ABHD10 activity may explain variability in mycophenolate pharmacokinetics.
• Provides a target for drug-drug interaction studies involving glucuronidation and deglucuronidation.
• Contributes to the detoxification of reactive acyl-glucuronide metabolites that can form covalent adducts.
• May play a role in the enterohepatic recirculation of mycophenolate.
• Offers a potential biomarker for predicting mycophenolate-related adverse effects.
• Highlights the importance of orphan esterases in drug development and safety assessment.
Molecular Mechanism of mycophenolic acid acyl-glucuronide esterase activity
Substrate Recognition and Binding
In simple terms: The enzyme recognizes and binds the substrate, mycophenolic acid acyl-glucuronide.
ABHD10, the enzyme responsible for GO:0102390, binds mycophenolic acid O-acyl-glucuronide with high specificity. The substrate is an acyl-glucuronide, where the glucuronic acid moiety is attached via an ester bond to the carboxyl group of mycophenolic acid. The enzyme's active site accommodates this bulky substrate, likely through hydrophobic interactions and hydrogen bonding. This binding step is essential for catalysis and determines the enzyme's substrate specificity.
Catalytic Hydrolysis
In simple terms: The enzyme cleaves the ester bond using water, releasing the active drug.
The catalytic mechanism of ABHD10 involves a serine hydrolase triad, typically composed of a serine nucleophile, a histidine, and an aspartate or glutamate. The serine residue attacks the ester carbonyl, forming an acyl-enzyme intermediate. Water then hydrolyzes this intermediate, releasing mycophenolate, a proton, and D-glucopyranuronate. This two-step process is characteristic of serine hydrolases and is essential for the deglucuronidation reaction.
Cofactors and Cofactor Independence
In simple terms: No special cofactors are needed; the enzyme uses water directly.
Unlike some esterases that require metal ions or other cofactors, ABHD10 catalyzes the hydrolysis of mycophenolic acid acyl-glucuronide without the need for exogenous cofactors. The reaction uses water as a nucleophile, and the enzyme's active site residues facilitate the cleavage. This cofactor independence simplifies the regulation and makes the enzyme versatile in various cellular contexts.
Regulation of Enzyme Activity
In simple terms: The activity can be regulated by expression levels and potential inhibitors.
The activity of ABHD10 can be regulated at the transcriptional level, and its expression may vary among individuals. Additionally, serine hydrolase inhibitors such as phenylmethylsulfonyl fluoride (PMSF) can inhibit its activity, suggesting that post-translational modifications or endogenous inhibitors might modulate its function. However, specific regulatory mechanisms remain to be fully elucidated. Understanding these regulatory pathways could provide insights into interindividual variability in drug metabolism.
Key Genes Involved in GO:0102390 mycophenolic acid acyl-glucuronide esterase activity
The following genes and proteins are directly or indirectly involved in mycophenolic acid acyl-glucuronide esterase activity and related metabolic pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABHD10 | Primary enzyme catalyzing the hydrolysis of mycophenolic acid acyl-glucuronide | Key target for studying deglucuronidation and drug metabolism |
| UGT1A9 | UDP-glucuronosyltransferase that forms mycophenolic acid acyl-glucuronide | Determines the formation of the substrate for ABHD10 |
| UGT2B7 | UDP-glucuronosyltransferase involved in mycophenolic acid glucuronidation | Contributes to the production of acyl-glucuronide metabolites |
| ABHD12 | Related alpha/beta hydrolase with esterase activity | Potential alternative enzyme for acyl-glucuronide hydrolysis |
| ABHD6 | Alpha/beta hydrolase domain-containing protein with hydrolase activity | May share substrate overlap with ABHD10 |
| CES1 | Carboxylesterase 1, a major drug-metabolizing esterase | Can hydrolyze various ester drugs but not mycophenolic acid acyl-glucuronide |
| CES2 | Carboxylesterase 2, involved in intestinal drug metabolism | May contribute to local deglucuronidation in the gut |
| AADAC | Arylacetamide deacetylase, an orphan esterase | Represents other orphan esterases with unknown physiological roles |
| ABHD11 | Alpha/beta hydrolase domain-containing protein 11 | Potential esterase with unknown substrate specificity |
| ABHD13 | Alpha/beta hydrolase domain-containing protein 13 | May have similar catalytic mechanism |
| ABHD14A | Alpha/beta hydrolase domain-containing protein 14A | Orphan esterase with potential drug metabolism roles |
| ABHD14B | Alpha/beta hydrolase domain-containing protein 14B | Orphan esterase with potential drug metabolism roles |
| ABHD15 | Alpha/beta hydrolase domain-containing protein 15 | Orphan esterase with potential drug metabolism roles |
| ABHD16A | Alpha/beta hydrolase domain-containing protein 16A | Orphan esterase with potential drug metabolism roles |
| ABHD17A | Alpha/beta hydrolase domain-containing protein 17A | Orphan esterase with potential drug metabolism roles |
| ABHD17B | Alpha/beta hydrolase domain-containing protein 17B | Orphan esterase with potential drug metabolism roles |
| ABHD17C | Alpha/beta hydrolase domain-containing protein 17C | Orphan esterase with potential drug metabolism roles |
How Is mycophenolic acid acyl-glucuronide esterase activity Regulated?
The activity of ABHD10, the enzyme responsible for GO:0102390, is primarily regulated at the level of gene expression, which can vary among individuals due to genetic polymorphisms or environmental factors. Additionally, serine hydrolase inhibitors can modulate its activity in vitro, suggesting potential post-translational regulation. However, specific regulatory pathways, such as transcriptional regulators or signaling cascades, have not been fully defined. Further research is needed to elucidate how this activity is controlled in vivo and how it contributes to drug metabolism variability.
mycophenolic acid acyl-glucuronide esterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABHD10 | Mycophenolate-related gastrointestinal toxicity | ABHD10 knockout mice or human liver organoids |
| ABHD10 | Drug-induced liver injury from acyl-glucuronide metabolites | Hepatocyte-specific ABHD10 knockout mice |
| UGT1A9 | Altered mycophenolate pharmacokinetics | UGT1A9 humanized mice |
| UGT2B7 | Mycophenolate metabolite accumulation | UGT2B7 knockout cell lines |
| ABHD10 | Interindividual variability in drug response | Patient-derived iPSC hepatocytes with ABHD10 polymorphisms |
Mycophenolate-Related Toxicity in Transplant Patients
Mycophenolic acid acyl-glucuronide, the substrate of GO:0102390, has been associated with gastrointestinal toxicity in transplant recipients. The accumulation of this metabolite can cause adverse effects, and the deglucuronidation activity of ABHD10 may mitigate toxicity by converting it back to the active drug. Interindividual differences in ABHD10 activity could therefore influence susceptibility to mycophenolate-related side effects.
Drug-Induced Toxicity and Orphan Esterases
Orphan esterases, including ABHD10, are increasingly recognized for their roles in drug-induced toxicity. Acyl-glucuronide metabolites of various drugs can be reactive and form covalent adducts with proteins, leading to idiosyncratic adverse reactions. The esterase activity of ABHD10 may protect against such toxicity by hydrolyzing these metabolites. Understanding this pathway could aid in predicting and preventing drug-induced liver injury.
Interindividual Variability in Drug Metabolism
Genetic and environmental factors can affect the expression and activity of ABHD10, leading to variability in mycophenolate pharmacokinetics. This variability can impact drug efficacy and toxicity, making it important to study the regulation of GO:0102390. Personalized dosing strategies could benefit from assessing ABHD10 activity in patients.
From mycophenolic acid acyl-glucuronide esterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ABHD10 deficiency alter mycophenolate pharmacokinetics? | ABHD10 knockout mouse |
| What is the effect of a catalytic serine mutation on ABHD10 activity? | Point mutation (S122A) knock-in cell line |
| Can we tag ABHD10 to study its localization? | Knock-in of FLAG-tagged ABHD10 |
| Does overexpression of ABHD10 enhance deglucuronidation? | ABHD10 overexpression in HEK293 cells |
| What are the off-target effects of ABHD10 inhibitors? | CRISPR library screening for resistance |
| Can we model human ABHD10 polymorphism in vivo? | Humanized ABHD10 mouse model |
How to Study the mycophenolic acid acyl-glucuronide esterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Quantification of mycophenolate and its metabolites | Enzyme kinetics and drug metabolism studies |
| qRT-PCR | ABHD10 mRNA expression levels | Gene expression analysis in tissues |
| Western blot | ABHD10 protein levels | Validation of expression changes |
| CRISPR knockout screening | Identification of genes affecting drug sensitivity | Functional genomics of drug metabolism |
| Activity-based protein profiling | Active serine hydrolases in proteomes | Enzyme discovery and inhibitor profiling |
| Immunofluorescence | Subcellular localization of ABHD10 | Cell biology studies |
| Recombinant enzyme assay | Direct catalytic activity of purified ABHD10 | Mechanistic studies |
Enzymatic Activity Assays
To measure mycophenolic acid acyl-glucuronide esterase activity, researchers can use LC-MS/MS to quantify the formation of mycophenolate from mycophenolic acid acyl-glucuronide in liver microsomes or recombinant enzyme preparations. This method provides direct evidence of catalytic activity and can be used to screen for inhibitors or assess kinetic parameters.
Gene Expression Analysis
Quantitative RT-PCR and Western blotting can be used to measure ABHD10 mRNA and protein levels in tissues or cell lines. These methods help correlate expression with activity and identify regulatory mechanisms. RNA-seq can provide a global view of esterase expression profiles.
CRISPR-Based Genetic Screens
CRISPR knockout libraries can be used to identify genes that modulate sensitivity to mycophenolic acid acyl-glucuronide or its metabolites. Such screens can uncover novel regulators of this pathway and potential therapeutic targets.
Proteomic and Activity-Based Protein Profiling
Activity-based protein profiling (ABPP) using serine hydrolase probes can assess the active state of ABHD10 and other esterases in complex proteomes. This technique allows for the identification of off-target effects of inhibitors and the discovery of new enzymes with similar activities.
How CRISPR Can Be Used to Study GO:0102390 mycophenolic acid acyl-glucuronide esterase activity
Knockout
CRISPR-Cas9 knockout of ABHD10 in human cell lines (e.g., HepG2 or HEK293) can abolish mycophenolic acid acyl-glucuronide esterase activity, providing a clean model to study the consequences of enzyme deficiency. Such knockouts can be used to assess the contribution of ABHD10 to drug metabolism and toxicity.
Point Mutation
Introducing point mutations in the catalytic serine residue of ABHD10 (e.g., S122A) via CRISPR can generate enzyme-dead variants, allowing researchers to distinguish between catalytic activity and potential non-enzymatic functions. These models are valuable for confirming the mechanism of action.
Knock-in
Knock-in of epitope tags (e.g., FLAG or HA) at the endogenous ABHD10 locus using CRISPR can facilitate studies of protein localization, interaction, and stability without altering expression levels. This approach preserves native regulation and provides a tool for proteomic analyses.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of ABHD10 can increase enzyme levels, enabling studies of enhanced deglucuronidation and its impact on drug efficacy. Overexpression models can also be used to test substrate specificity and inhibitor sensitivity.
How EDITGENE Supports mycophenolic acid acyl-glucuronide esterase activity Research
Researchers studying mycophenolic acid acyl-glucuronide esterase activity-related genes often need to determine whether a candidate gene is causally involved in drug metabolism, toxicity, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for mycophenolic acid acyl-glucuronide esterase activity research.
Frequently Asked Questions About mycophenolic acid acyl-glucuronide esterase activity
What is mycophenolic acid acyl-glucuronide esterase activity?
It is an enzymatic activity (GO:0102390) that hydrolyzes mycophenolic acid acyl-glucuronide to release mycophenolate, a proton, and D-glucopyranuronate.
What gene encodes the enzyme for this activity?
The primary enzyme is ABHD10 (alpha/beta hydrolase domain-containing protein 10).
What is the substrate of this enzyme?
The substrate is mycophenolic acid O-acyl-glucuronide(1-), a metabolite of the immunosuppressant mycophenolate.
What is the product of the reaction?
The products are mycophenolate, a proton, and D-glucopyranuronate.
Why is this activity important in transplantation?
It regenerates active mycophenolate from its acyl-glucuronide metabolite, potentially affecting drug efficacy and toxicity in transplant patients.
What diseases are associated with this activity?
Altered activity may contribute to mycophenolate-related gastrointestinal toxicity and interindividual variability in drug response.
How can I study this activity in the lab?
You can use LC-MS/MS enzyme assays, CRISPR knockout models, and activity-based protein profiling.
What are the research methods for this GO term?
Common methods include enzymatic assays, gene expression analysis, CRISPR screens, and proteomics.
Is ABHD10 the only enzyme with this activity?
ABHD10 is the major enzyme identified, but other orphan esterases may have overlapping activity.
How does this activity relate to drug metabolism?
It is part of the phase II metabolism of mycophenolic acid, influencing drug clearance and exposure.
Conclusion
Mycophenolic acid acyl-glucuronide esterase activity (GO:0102390) is a key enzymatic function in drug metabolism, primarily mediated by ABHD10. It regulates the balance between active mycophenolate and its acyl-glucuronide metabolite, with implications for immunosuppressive therapy and drug-induced toxicity. Understanding this activity through CRISPR-based models and biochemical assays can inform personalized medicine and improve transplant outcomes. EDITGENE provides the tools and expertise to study this pathway in depth.
References
- 1. Fukami T et al.. 2012. The emerging role of human esterases.. Drug Metab Pharmacokinet 27(5):466-77 PMID: 22813719
- 2. Fukami T. 2015. [Role of Human Orphan Esterases in Drug-induced Toxicity].. Yakugaku Zasshi 135(11):1235-44 PMID: 26521872
- 3. Iwamura A et al.. 2012. Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver.. J Biol Chem 287(12):9240-9 PMID: 22294686
- 4. Staatz CE et al.. 2007. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.. Clin Pharmacokinet 46(1):13-58 PMID: 17201457
